Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0H2JQ
|
||||
| Former ID |
DIB014312
|
||||
| Drug Name |
NB-506
|
||||
| Synonyms |
J-107185; L-753000; N-[12-(beta-D-Glucopyranosyl)-1,11-dihydroxy-5,7-dioxo-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-6-yl]formamide; 6-(Formamido)-12-(beta-D-glucopyranosyl)-1,11-dihydroxy-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione
|
||||
| Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Discontinued in Phase 2 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| CAS Number |
CAS 151069-12-4
|
||||
| Target and Pathway | |||||
| Target(s) | Human DNA | Target Info | Inhibitor | [2] | |
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005106) | ||||
| REF 2 | DNA binding properties of the indolocarbazole antitumor drug NB-506. Anticancer Drug Des. 2001 Apr-Jun;16(2-3):99-107. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.